Six months ago, the pharmaceutical sector was riding high, buoyed by its defensive merits and corp...
Six months ago, the pharmaceutical sector was riding high, buoyed by its defensive merits and corporate activity. Since then, the sector has fallen sharply relative to a depressed stock market. Concerns regarding a string of patent expiries, together with news that a number of high-profile drugs have failed to meet market expectations, have dampened sentiment towards the sector. However, none of this news is particularly new. The market has known about the glut of patent expiries for a number of years and has also witnessed a steady fall in the number of drug discoveries since 199...
To continue reading this article...
Join Professional Adviser for free
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes